Seegene, Hologic MDx Collaboration
News Nov 07, 2016
Seegene Inc. announced it has entered a collaboration agreement with Hologic to develop and supply high multiplex real-time PCR reagents for the Hologic Panther Fusion™ system that is currently in development.
Under the terms of the agreement, Seegene will develop and manufacture multiplex assays based on DPO™, TOCE™, and MuDT™ technologies for Hologic’s next generation molecular diagnostics platform, the Panther Fusion™ system. Hologic, in turn, will obtain worldwide commercialization rights to these assays. Financial terms of the agreement were not disclosed.
Hologic Diagnostic President Tom West said, “We are pleased to partner with Seegene and incorporate their innovative technologies with our system. Seegene’s multiplex reagents will enable simultaneous detection and quantification of various target genes, further broadening the menu of Hologic’s Panther Fusion™ system and strengthening its leadership position in the molecular diagnostic market.”
Seegene expands tremendous effort to continually develop and commercialize innovative high multiplex PCR technologies that enable more accurate and cost-effective molecular diagnostics. MuDT™ technology provides perfection of qPCR technology by simultaneously identifying and quantifying multiple targets in a single fluorescence channel.
Dr. Jong-Yoon Chun, Founder and CEO of Seegene said, “Our agreement with Hologic represents another meaningful milestone to Seegene’s global expansion initiatives in the molecular diagnostics market. We expect to accelerate technological standardization in the MDx market by building up capabilities of assay development applying on various platforms.”
Story from Seegene. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019